Alzamend Neuro ALZN

Drug Manufacturers - General, Healthcare

$1.13

+0.89%

Market cap: $5.5M
PE: n/m; a loss over the last year
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; a loss over the last year
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: n/m; not a meaningful number

Alzamend Neuro's trailing earnings are negative, so it has no PE.

Charts

Financials

Income statement for ALZN, by quarter
Income statement	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
R&D	$2M+30%	$1.9M−34%	$183.4K−89%	$206.6K−91%	$311.1K−84%	$447.1K−77%	$450.2K+145%	$1.7M+743%	$176.3K−43%	$1.3M+186%	$434K−4%	$1.1M−38%
SG&A	$904.9K−43%	$751.2K−70%	$666.6K−60%	$755.8K−35%	$1M+16%	$590.3K−21%	$688.8K+3%	$959.3K+27%	$821.8K−22%	$919K+56%	$2.4M+254%	$1.9M+102%
	−$2.9M−7%	−$2.7M−51%	−$850.1K−74%	−$962.4K−73%	−$1.4M−53%	−$1M−61%	−$1.1M+34%	−$2.7M+181%	−$998.1K−27%	−$2.2M+112%	−$2.9M+152%	−$3M+12%
Interest expense	$4.3K+20%	$2.5K+21%	$1.5K+182%	$12K+554%	$3.5K−19%	$2K−19%	$509−65%	$2.5K−79%	$2.6K−24%	$1.3K−34%	$150−71%	$2K−19%
Net income	−$2.9M−7%	−$2.7M−51%	−$851.5K−74%	−$974.4K−72%	−$1.4M−53%	−$1M−61%	−$1.1M+34%	−$2.7M+177%	−$1M−27%	−$2.2M+112%	−$2.9M+152%	−$3M+12%
	−$39.87−8%	−$33.93−55%	−$11.69−75%	−$11.42−76%	−$3.61−91%	−$1.75−95%	−$2.27−81%	−$1.28−89%	−$0.30−92%	−$0.58−67%	−$0.72−68%	−$0.68−47%
	72.9K+1%	78.4K+8%	72.8K+2%	85.3K+17%	392.4K+438%	612K+681%	723.5K+893%	2.1M+2369%	3.4M+762%	3.8M+522%	4M+453%	4.5M+113%

EPS, diluted: 6 periods, Q4 FY22 to Q4 FY26: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 276, the two on one basis (x15). Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 276, the two on one basis (x9.016). Q4 FY25 and Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Alzamend Neuro's size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
ALZNAlzamend Neuro	$5.5M	n/m	n/a	n/m	n/m	n/m
OXBROXBRIDGE RE HOLDINGS	$7.7M	47.5×	9.6×	2.8×	+40%	4.7%
EDUCEducational Development	$8.7M	5.4×	11.3×	0.4×	−32%	8.6%
GTIMGood Times Restaurants	$13.6M	6.1×	13.6×	0.1×	−6%	1.7%
MDRRMedalist Diversified	$15.4M	2.5×	3.0×	1.6×	−1%	80.2%
BCGBinah Capital	$18.2M	6.7×	20.8×	0.1×	+8%	2.2%
VIPVulcan Infrastructure & Power	$19.6M	17.9×	24.4×	0.4×	−14%	1.0%
MXCMexco Energy	$20.5M	13.4×	13.3×	3.0×	−9%	23.3%
CKXCKX Lands	$21.5M	7.4×	32.6×	31.0×	−17%	n/m
MSGMMotorsport Games	$22.5M	11.4×	11.5×	1.5×	+79%	16.2%
ATCHAtlasClear	$24M	15.8×	17.5×	1.2×	+85%	9.8%
Peer median	$18.9M	9.4×	13.4×	1.4×	−3%	8.6%